Faculty Opinions recommendation of Phase 3, randomized, placebo-controlled study of zibotentan (ZD4054) in patients with castration-resistant prostate cancer metastatic to bone.

Phase 3 ◽

MP34-17 A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ENZALUTAMIDE IN PATIENTS WITH NONMETASTATIC CASTRATION-RESISTANT PROSTATE CANCER: POST HOC ANALYSIS OF PROSPER BY PROSTATE SPECIFIC-ANTIGEN PROGRESSION

The Journal of Urology ◽

10.1097/01.ju.0000555909.47437.02 ◽

2019 ◽

Vol 201 (Supplement 4) ◽

Author(s):

Fred Saad* ◽

Cora N. Sternberg ◽

Eleni Efstathiou ◽

Karim Fizazi ◽

Katharina Modelska ◽

...

Keyword(s):

Prostate Cancer ◽

Specific Antigen ◽

Controlled Study ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Post Hoc Analysis ◽

Castration Resistant ◽

Post Hoc

Phase 3, randomized, placebo-controlled study of zibotentan (ZD4054) in patients with castration-resistant prostate cancer metastatic to bone

Cancer ◽

10.1002/cncr.27674 ◽

2012 ◽

Vol 118 (22) ◽

pp. 5709-5718 ◽

Cited By ~ 72

Author(s):

Joel B. Nelson ◽

Karim Fizazi ◽

Kurt Miller ◽

Celestia Higano ◽

Judd W. Moul ◽

...

Keyword(s):

Prostate Cancer ◽

Controlled Study ◽

Phase 3 ◽

Reply to Johann S. de Bono, Maha Hussain, and Jinyu Kang’s Letter to the Editor re: Konrad H. Stopsack. Efficacy of PARP Inhibition in Metastatic Castration-resistant Prostate Cancer is Very Different with Non-BRCA DNA Repair Alterations: Reconstructing Prespecified Endpoints for Cohort B from the Phase 3 PROfound Trial of Olaparib. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.09.024

European Urology ◽

10.1016/j.eururo.2020.12.018 ◽

2020 ◽

Author(s):

Konrad H. Stopsack

Keyword(s):

Prostate Cancer ◽

Dna Repair ◽

Parp Inhibition ◽

Phase 3 ◽

Castration Resistant ◽

Letter To The Editor

Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial

The Lancet ◽

10.1016/s0140-6736(21)00580-8 ◽

2021 ◽

Vol 398 (10295) ◽

pp. 131-142

Author(s):

Christopher Sweeney ◽

Sergio Bracarda ◽

Cora N Sternberg ◽

Kim N Chi ◽

David Olmos ◽

...

Keyword(s):

Prostate Cancer ◽

Phase 3 ◽

Double Blind ◽

Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study

European Urology ◽

10.1016/j.eururo.2016.07.032 ◽

2017 ◽

Vol 71 (2) ◽

pp. 151-154 ◽

Cited By ~ 120

Author(s):

Tomasz M. Beer ◽

Andrew J. Armstrong ◽

Dana Rathkopf ◽

Yohann Loriot ◽

Cora N. Sternberg ◽

...

Keyword(s):

Prostate Cancer ◽

Phase 3 ◽

Castration Resistant ◽

Extended Analysis

A phase 3, randomized, double-blind trial of nivolumab or placebo combined with docetaxel for metastatic castration-resistant prostate cancer (CheckMate 7DX)

10.26226/morressier.613756f1842293c031b5830d ◽

2021 ◽

Author(s):

Karim Fizazi

Keyword(s):

Prostate Cancer ◽

Double Blind Trial ◽

Phase 3 ◽

Double Blind ◽

Blind Trial ◽

Cabozantinib Versus Mitoxantrone-prednisone in Symptomatic Metastatic Castration-resistant Prostate Cancer: A Randomized Phase 3 Trial with a Primary Pain Endpoint

European Urology ◽

10.1016/j.eururo.2018.11.033 ◽

2019 ◽

Vol 75 (6) ◽

pp. 929-937 ◽

Cited By ~ 11

Author(s):

Ethan M. Basch ◽

Mark Scholz ◽

Johann S. de Bono ◽

Nicholas Vogelzang ◽

Paul de Souza ◽

...

Keyword(s):

Prostate Cancer ◽

Phase 3 ◽

713 ABIRATERONE ACETATE IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS WITHOUT PRIOR CHEMOTHERAPY - INTERIM ANALYSIS OF THE COU-AA-302 PHASE 3 TRIAL

The Journal of Urology ◽

10.1016/j.juro.2013.02.272 ◽

2013 ◽

Vol 189 (4S) ◽

Cited By ~ 1

Author(s):

Fred Saad ◽

Neal D Shore ◽

Hendrik Van Poppel ◽

Dana Rathkopf ◽

Matthew R. Smith ◽

...

Keyword(s):

Prostate Cancer ◽

Cancer Patients ◽

Interim Analysis ◽

Abiraterone Acetate ◽

Phase 3 ◽

Prior Chemotherapy ◽

Phase II randomized, double-blind, placebo-controlled study of tivantinib in men with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC)

Investigational New Drugs ◽

10.1007/s10637-018-0630-9 ◽

2018 ◽

Vol 36 (5) ◽

pp. 919-926 ◽

Cited By ~ 1

Author(s):

Paul Monk ◽

Glenn Liu ◽

Walter M. Stadler ◽

Susan Geyer ◽

Ying Huang ◽

...

Keyword(s):

Prostate Cancer ◽

Phase Ii ◽

Controlled Study ◽

Double Blind ◽

Double Blind Placebo ◽

Patient-reported outcomes following enzalutamide or placebo in men with non-metastatic, castration-resistant prostate cancer (PROSPER): a multicentre, randomised, double-blind, phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(18)30898-2 ◽

2019 ◽

Vol 20 (4) ◽

pp. 556-569 ◽

Cited By ~ 30

Author(s):

Bertrand Tombal ◽

Fred Saad ◽

David Penson ◽

Maha Hussain ◽

Cora N Sternberg ◽

...

Keyword(s):

Prostate Cancer ◽

Patient Reported Outcomes ◽

Phase 3 ◽

Double Blind ◽

Castration Resistant ◽

Patient Reported